Related Experiment Video
Updated: Nov 6, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Tumor-treating fields (TTFields)-based cocktail therapy: a novel blueprint for glioblastoma treatment
Minjie Wang1, Chaocai Zhang2, Xuan Wang1
1Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430022, China.
Abstract:
Glioblastoma is one of the most common malignant tumors in the central nervous system. Due to the high plasticity, heterogeneity and complexity of the tumor microenvironment, these tumors are resistant to almost all therapeutic strategies when they reach an advanced stage. Along with being a unique and effective way to kill cancer cells, tumor-treating fields (TTFields) has emerged as a breakthrough among glioblastoma therapies since the advent of temozolomide (TMZ), and the combination of these treatments has gradually been promoted and applied in the clinic. The combination of TTFields with other therapies is particularly suitable for this type of "cold" tumors and has attracted a large amount of attention from clinicians and researchers in the era of cancer cocktail therapy. Here, we introduced the current treatment regimen for glioblastoma, highlighting the unique advantages of TTFields in the treatment of glioblastoma. Then, we summarized current glioblastoma clinical trials that combine TTFields and other therapies. In addition, the main and potential mechanisms of TTFields were introduced to further understand the rationale for each combination therapy. Finally, we focused on the most advanced technologies applied in glioblastoma research and treatment and the prospect of their combination with TTFields. This review provides a unique overview of glioblastoma treatment.
Insights
Tumor-treating fields (TTFields) offer a novel approach for glioblastoma, a challenging brain cancer. Combining TTFields with other therapies shows promise for improving treatment outcomes in this complex disease.
Area of Science:
- Neuro-oncology
- Cancer Therapy
- Biomedical Engineering
Background:
- Glioblastoma is a highly aggressive brain tumor with poor prognosis.
- Tumor microenvironment complexity and heterogeneity contribute to therapeutic resistance.
- Temozolomide (TMZ) is a standard chemotherapy, but resistance is common.
Purpose of the Study:
- To review current glioblastoma treatment strategies.
- To highlight the role and advantages of TTFields in glioblastoma therapy.
- To explore TTFields combination therapies and future directions.
Main Methods:
- Literature review of glioblastoma treatments.
- Analysis of clinical trials combining TTFields with other therapies.
- Discussion of TTFields mechanisms of action.
- Overview of advanced technologies in glioblastoma research.
Main Results:
- TTFields represent a breakthrough therapy for glioblastoma.
- Combination of TTFields with other treatments is increasingly used.
- TTFields demonstrate unique advantages against "cold" tumors.
- Mechanisms of TTFields action are being elucidated.
Conclusions:
- TTFields hold significant potential as a glioblastoma treatment modality.
- Combination therapies involving TTFields are a promising area of research.
- Integration of advanced technologies with TTFields may further enhance treatment efficacy.

